Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20794007 | 1.00 | ALDH1A1 (0.43) | ALDH1A1ATMBRD4RIPK1CHRNB2 | |
| SCHEMBL8035590 | 0.81 | ALDH1A1 (0.38) | ALDH1A1ATMBRD4RIPK1KMT2A | |
| SCHEMBL10533429 | 0.79 | RIPK1 (0.52) | ALDH1A1ATMBRD4RIPK1CHRNB2 | |
| SCHEMBL10041517 | 0.79 | RIPK1 (0.52) | ALDH1A1ATMBRD4RIPK1CHRNB2 | |
| SCHEMBL20794010 | 0.79 | RIPK1 (0.52) | ALDH1A1ATMBRD4RIPK1CHRNB2 | |
| SCHEMBL20780480 | 0.74 | TACR1 (0.37) | — | |
| SCHEMBL22728675 | 0.73 | RIPK1 (0.45) | ALDH1A1ATMBRD4RIPK1CHRNB2 | |
| SCHEMBL20794089 | 0.70 | CETP (0.33) | P2RX7 | |
| SCHEMBL14554141 | 0.69 | MAPT (0.37) | KMT2AMEN1MAPTTSHRP2RX7 | |
| SCHEMBL6439879 | 0.68 | GAA (0.44) | ALDH1A1ATMBRD4RIPK1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | ALDH1A1 4145/4885ATM 1051/4885BRD4 1883/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | ALDH1A1 2904/4885ATM 1642/4885BRD4 856/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | ALDH1A1 1804/4885ATM 564/4885BRD4 643/4885 |
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | ALDH1A1 4145/4885ATM 1051/4885BRD4 1883/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | ALDH1A1 2465/4885ATM 837/4885BRD4 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.